Update of influenza vaccine strains in Europe. Quality issues
Abstract
In 2009-2010 there was an influenza pandemic that occurred despite all preventive measures. Analysis of this pandemic revealed some gaps in the regulatory requirements applied both to the development of new influenza vaccines and to the change/update of the seasonal influenza vaccine strains. Taking into account the lessons learned from this pandemic the European Medicines Agency revised the existing guidelines in 2014-2016 and proposed new recommendations on quality evaluation and conduct of non-clinical and clinical trials in the development of influenza vaccines. The revised requirements encompass not only quality evaluation issues, but also changes/update of strain composition of seasonal, pre-pandemic and pandemic influenza vaccines. The experience acquired by the Agency can help update the Russian regulatory framework in order to improve efficacy and safety of influenza vaccines.
About the Authors
A. A. Soldatov
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Chief expert of the Division for Expert Evaluation of Allergenes, Cytokines and other Immunomodulators of the Centre for Evaluation and Control of Medicinal Immunobiological Products. Doctor of Medical Sciences
Russian Federation
Chief expert of the Division for Expert Evaluation of Allergenes, Cytokines and other Immunomodulators of the Centre for Evaluation and Control of Medicinal Immunobiological Products. Doctor of Medical Sciences
Zh. I. Avdeeva
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Chief expert of the Division for Expert Evaluation of Allergenes, Cytokines and other Immunomodulators of the Centre for Evaluation and Control of Medicinal Immunobiological Products. Doctor of Medical Sciences, professor
Russian Federation
Chief expert of the Division for Expert Evaluation of Allergenes, Cytokines and other Immunomodulators of the Centre for Evaluation and Control of Medicinal Immunobiological Products. Doctor of Medical Sciences, professor
V. P. Bondarev
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Director of the Centre for Evaluation and Control of Medicinal Immunobiological Products. Doctor of Medical Sciences, professor
Russian Federation
Director of the Centre for Evaluation and Control of Medicinal Immunobiological Products. Doctor of Medical Sciences, professor
References
1. Shchelkanov MYu, Lvov DK. Genotypic structure of the genus Influenza A virus. Annals of the Russian academy of medical sciences 2011; (5): 19–23 (in Russian).
2. Kolobukhina LV, Shchelkanov MYu, Merkulova LN, Bazarova MV, Burtseva EI, et al. Etiotropic therapy of influenza: lessons from the last pandemic. Annals of the Russian academy of medical sciences 2011; (5): 35–40 (in Russian).
3. Ghendon YuZ. Swine-origin influenza H1N1 / California — passions and facts. Journal of Microbiology, Epidemiology and Immunology 2010; (3): 105–14 (in Russian).
4. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325(5937): 197–201.
5. Smith GJ, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 2009; 459(7250): 1122–5.
6. Guideline on influenza vaccines — quality module (25 April 2014. EMA/CHMP/BWP/310834/2012). Available from: https://goo.gl/ xOnHht.
7. Guideline on influenza vaccines. Non-clinical and clinical module (21 July 2016. EMA/CHMP/VWP/457259/2014). Available from: https://goo.gl/6AoNPn.
8. Guideline on influenza vaccines — submission and procedural requirements. Regulatory and procedural requirements module. (May 2015 EMA/56793/2014). Available from: https://goo.gl/ YIy7zd.
9. Vaccines for human use. European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ep900.
10. Influenza vaccine (split virion, inactivated). European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ep900.
11. Influenza vaccine (surface antigen, inactivated). European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ep900.
12. Influenza vaccine (whole virion, inactivated). European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ep900.
13. Influenza vaccine (surface antigen, inactivated, virosome). European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ ep900.
14. Influenza vaccine (whole virion, inactivated, prepared in cell cultures). European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ep900.
15. Influenza vaccine (surface antigen, inactivated, prepared in cell cultures). European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ep900.
16. WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines. WHO Technical Report Series No 941, 2007 Annex 5.
17. Q5C Note for Guidance on Quality of Biotechnological Products: Stability testing of biotechnological/biological products (CPMP/ICH/ 138/95). 18. 2.6.
18. Tests for neurovirulence of live virus vaccines. European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ ep900.
19. Ward AC. Neurovirulence of influenza A virus. J Neurovirol. 1996; 2(3): 139–51.
20. World Health Organization. WHO Technical Report Series, No. 927, 2005 Annex 4. Requirements for the use of animal cells as in vitro substrates for the production of biologicals (Addendum 2003). Available from: https://goo.gl/f1J3w0.
21. CPMP Note for guidance on virus validation studies. The design, contribution and interpretation of studies validating the inactivation and removal of viruses (CPMP/BWP/268/95). Available from: https://goo.gl/GepjYR. 22. 5.2.2. Chicken flocks free from specified pathogens for the production and quality control of vaccines. European Pharmacopoiea 9.0. Available from: http://online6.edqm.eu/ep900.
Review
For citations:
Soldatov A.A., Avdeeva Zh.I., Bondarev V.P. Update of influenza vaccine strains in Europe. Quality issues. BIOpreparations. Prevention, Diagnosis, Treatment. 2017;17(1):3-12. (In Russ.)
Views:
638
Email this article 